ATE108774T1 - Isoindolonderivate, ihre herstellung und ihre verwendung als zwischenprodukte zur herstellung von substanz-p-antagonisten. - Google Patents

Isoindolonderivate, ihre herstellung und ihre verwendung als zwischenprodukte zur herstellung von substanz-p-antagonisten.

Info

Publication number
ATE108774T1
ATE108774T1 AT90403300T AT90403300T ATE108774T1 AT E108774 T1 ATE108774 T1 AT E108774T1 AT 90403300 T AT90403300 T AT 90403300T AT 90403300 T AT90403300 T AT 90403300T AT E108774 T1 ATE108774 T1 AT E108774T1
Authority
AT
Austria
Prior art keywords
production
derivatives
antagonists
substance
intermediate products
Prior art date
Application number
AT90403300T
Other languages
English (en)
Inventor
Marie-Christine Dubroeucq
Claude Moutonnier
Jean-Francois Peyronel
Michel Tabart
Alain Truchon
Original Assignee
Rhone Poulenc Sante
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Sante filed Critical Rhone Poulenc Sante
Application granted granted Critical
Publication of ATE108774T1 publication Critical patent/ATE108774T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT90403300T 1989-11-23 1990-11-22 Isoindolonderivate, ihre herstellung und ihre verwendung als zwischenprodukte zur herstellung von substanz-p-antagonisten. ATE108774T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8915407A FR2654726B1 (fr) 1989-11-23 1989-11-23 Nouveaux derives de l'isoindolone et leur preparation.

Publications (1)

Publication Number Publication Date
ATE108774T1 true ATE108774T1 (de) 1994-08-15

Family

ID=9387708

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90403300T ATE108774T1 (de) 1989-11-23 1990-11-22 Isoindolonderivate, ihre herstellung und ihre verwendung als zwischenprodukte zur herstellung von substanz-p-antagonisten.

Country Status (23)

Country Link
US (1) US5112988A (de)
EP (1) EP0430771B1 (de)
JP (1) JPH03176468A (de)
KR (1) KR910009660A (de)
AT (1) ATE108774T1 (de)
AU (1) AU635984B2 (de)
CA (1) CA2030570A1 (de)
DE (1) DE69010851T2 (de)
DK (1) DK0430771T3 (de)
ES (1) ES2057488T3 (de)
FI (1) FI94627C (de)
FR (1) FR2654726B1 (de)
HU (1) HU214574B (de)
IE (1) IE64737B1 (de)
IL (1) IL96447A (de)
NO (1) NO174148C (de)
NZ (1) NZ236175A (de)
PL (2) PL164955B1 (de)
PT (1) PT95983B (de)
RU (1) RU2104269C1 (de)
SK (1) SK278474B6 (de)
YU (1) YU47437B (de)
ZA (1) ZA909370B (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676442B1 (fr) * 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveau derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2688219B1 (fr) 1992-03-03 1994-07-08 Sanofi Elf Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant.
FR2689889B1 (fr) * 1992-04-10 1994-06-10 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole, et leur preparation.
US5830854A (en) * 1992-12-14 1998-11-03 Merck Sharp & Dohme, Limited Method of treating cystic fibrosis using a tachykinin receptor antagonist
FR2703679B1 (fr) * 1993-04-05 1995-06-23 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2709752B1 (fr) * 1993-07-30 1995-10-06 Rhone Poulenc Rorer Sa Nouveaux dérivés de perhydroisoindole, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2710913B1 (fr) * 1993-10-07 1995-11-24 Rhone Poulenc Rorer Sa Nouveaux dérivés de perhydroisoindole, leur préparation et les compositions pharmaceutiques qui les contiennent.
TW365603B (en) * 1993-07-30 1999-08-01 Rhone Poulenc Rorer Sa Novel perhydroisoindole derivatives, their preparation and pharmaceutical compositions which contain them
US5543530A (en) * 1993-12-23 1996-08-06 Ortho Pharmaceutical Corporation 4-arylisoindole analgesics
FR2728169A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2728165A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2729954B1 (fr) 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
FR2755013B1 (fr) * 1996-10-29 1998-11-27 Rhone Poulenc Rorer Sa Nouvelle application therapeutique des antagonistes de la substance p
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
KR100885986B1 (ko) 1999-11-03 2009-03-03 에이엠알 테크놀로지, 인크. 노르에피네프린, 도파민 및 세로토닌의 재흡수를 방지하기위한 아릴 및 헤테로아릴 치환된테트라하이드로이소퀴놀린 및 이들의 용도
CA2415532C (en) 2000-07-11 2010-05-11 Albany Molecular Research, Inc. Novel 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof
KR101389246B1 (ko) 2004-07-15 2014-04-24 브리스톨-마이어스스퀴브컴파니 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
EP1888050B1 (de) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. Cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropansäure zur Behandlug von Krebs
ZA200800440B (en) 2005-07-15 2009-12-30 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2805945B1 (de) 2007-01-10 2019-04-03 MSD Italia S.r.l. Amidsubstituierte Indazole als Poly-(ADP-Ribose)-Polymerase (PARP)-Hemmer
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
KR101830447B1 (ko) 2009-05-12 2018-02-20 알바니 몰레큘라 리써치, 인크. 7-([1,2,4]트리아졸로[1,5-α]피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도
CN102638982B (zh) 2009-05-12 2015-07-08 百时美施贵宝公司 (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
EP2429295B1 (de) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl-, heteroaryl- und heterocyclen-substituierte tetrahydroisochinoline und ihre verwendung
EP2488028B1 (de) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituierte piperidine zur erhöhung der p53-aktivität und ihre verwendung
PL2528922T3 (pl) * 2010-01-27 2018-01-31 Ab Pharma Ltd Związki poliheterocykliczne jako inhibitory hcv
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1基因表达的抑制
JP2013537423A (ja) 2010-08-17 2013-10-03 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸(siNA)を用いたB型肝炎ウイルス(HBV)遺伝子発現のRNA干渉媒介性阻害
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (de) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Kondensierte pyrazolderivate als neue erk-hemmer
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2699568A1 (de) 2011-04-21 2014-02-26 Piramal Enterprises Limited Kristalline form eines morpholinsulfonylindolderivat-salzes und verfahren zu seiner herstellung
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2844261B1 (de) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. Sina-zusammensetzungen
CN105050598B (zh) 2012-09-28 2018-04-27 默沙东公司 作为erk抑制剂的新型化合物
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (de) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Kreisförmige polynukleotide
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
EP3706742B1 (de) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5-inhibitoren
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833668B1 (de) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5-inhibitoren
EP3833667B1 (de) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5-inhibitoren

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2858314A (en) * 1954-06-07 1958-10-28 Georgian Vlasios Hydrocarbazolenines
US4042707A (en) * 1976-02-19 1977-08-16 E. I. Du Pont De Nemours And Company 3α-Arylhydroisoindoles
IT1113879B (it) * 1979-03-15 1986-01-27 Farmatis Spa Derivato isoindolinico,processo per la sua preparazione e composizioni terapeutiche che lo comprendono come principio attivo
US4494547A (en) * 1981-03-30 1985-01-22 North Carolina Central University 2H-isoindolediones, their synthesis and use as radiosensitizers
DE3133302A1 (de) * 1981-08-22 1983-03-03 Beiersdorf Ag, 2000 Hamburg Isoindolin-2-yl-amino-imidazoline und isoindolin-2-yl-guanidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP0091241B1 (de) * 1982-04-02 1988-12-28 Takeda Chemical Industries, Ltd. Kondensierte Pyrrolinon-Derivate, und ihre Herstellung
DE3688128D1 (de) * 1985-12-09 1993-04-29 Banyu Pharma Co Ltd Isoindolinderivate und verfahren zu ihrer herstellung.

Also Published As

Publication number Publication date
IE904234A1 (en) 1991-06-05
IE64737B1 (en) 1995-09-06
IL96447A0 (en) 1991-08-16
FI94627C (fi) 1995-10-10
IL96447A (en) 1995-03-15
ES2057488T3 (es) 1994-10-16
PT95983A (pt) 1991-09-13
US5112988A (en) 1992-05-12
PT95983B (pt) 1998-01-30
NO174148B (no) 1993-12-13
NZ236175A (en) 1993-03-26
PL164955B1 (en) 1994-10-31
YU223590A (sh) 1993-05-28
FI905770L (fi) 1991-05-24
KR910009660A (ko) 1991-06-28
YU47437B (sh) 1995-03-27
RU2104269C1 (ru) 1998-02-10
SK580690A3 (en) 1997-07-09
NO905067L (no) 1991-05-24
EP0430771A1 (de) 1991-06-05
FR2654726A1 (fr) 1991-05-24
PL164973B1 (pl) 1994-10-31
DE69010851D1 (de) 1994-08-25
SK278474B6 (en) 1997-07-09
AU635984B2 (en) 1993-04-08
HU214574B (hu) 1998-04-28
AU6682890A (en) 1991-05-30
PL287908A1 (en) 1991-12-02
DE69010851T2 (de) 1994-11-24
HU907249D0 (en) 1991-05-28
NO905067D0 (no) 1990-11-22
CA2030570A1 (fr) 1991-05-24
HUT55756A (en) 1991-06-28
NO174148C (no) 1994-03-23
FI94627B (fi) 1995-06-30
DK0430771T3 (da) 1994-08-29
FR2654726B1 (fr) 1992-02-14
JPH03176468A (ja) 1991-07-31
EP0430771B1 (de) 1994-07-20
ZA909370B (en) 1991-10-30
FI905770A0 (fi) 1990-11-22

Similar Documents

Publication Publication Date Title
ATE108774T1 (de) Isoindolonderivate, ihre herstellung und ihre verwendung als zwischenprodukte zur herstellung von substanz-p-antagonisten.
RU92004482A (ru) Производные изоиндола
ATE102923T1 (de) Isoindolonderivate, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE116295T1 (de) Perhydroisoindol derivate und ihre herstellung.
ATE50763T1 (de) Tetralin-derivate, ihre herstellung und verwendung.
MX9301986A (es) Derivados de perhidroisoindol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
DE69104314D1 (de) Verwendung von 1-[3-(Dimethylamino)propyl]-1-phenylphthalenen zur Behandlung zerebrovaskulärer Störungen.
ES545728A0 (es) Procedimiento para preparar 5h,11h-pirrolo (2,1c)-(1,4)ben- zoxazepinas sustituidas en posicion 11
ATE121395T1 (de) Cumarinderivate, ihre herstellung und ihre verwendung zur behandlung von zerebrovaskulären störungen.
FI893901A0 (fi) Menetelmä tetrasyklisten masennuslääkkeiden valmistamiseksi
DE58905079D1 (de) Neue alpha-aminocarbonsaeure-derivate, ihre herstellung und verwendung.
ATE188700T1 (de) Indol-2,3-dione-3-oximderivate, ihre herstellung und verwendung
FI861324A0 (fi) Nya (4.2.0) bicyclooktanderivat, som har vaerdefulla terapeutiska egenskaper.
ATE218138T1 (de) N-substituierte azabicycloheptan-derivate, ihre herstellung und verwendung
ATE98961T1 (de) 1,8-benzonaphthyridinderivate und ihre herstellung.
ATE56442T1 (de) 2,6-piperazin-dion-derivate, ihre verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ES2042727T3 (es) Acidos 1,3,4,9-tetrahidropirano(3,4-b)indol-1-acetico.
ATE97130T1 (de) 13-brom und 13, 14-dibrom-ergoline, ihre herstellung und verwendung in arzneimitteln.
ES2064692T3 (es) Nuevos derivados de la 2-acetidinona 1,3,4-trisustituidas y su procedimiento de sintesis asimetrica.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee